ABN Amro Investment Solutions Raises Position in Abbott Laboratories $ABT

Key Points

• ABN Amro Investment Solutions increased its Abbott Laboratories stake by 305.3% in the fourth quarter, bringing its holdings to 83,151 shares valued at about $10.4 million.
• Abbott’s recent quarter beat earnings and revenue estimates, with EPS of $1.15 versus $1.14 expected and revenue of $11.16 billion versus $10.99 billion expected. The company also raised guidance, including FY 2026 EPS guidance of 5.380–5.580.
• Despite the strong operating results, shares were trading lower around $87.72, while analysts maintained a Moderate Buy consensus with a target price of $119.43.

ABN Amro Investment Solutions raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 305.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,151 shares of the healthcare product maker's stock after purchasing an additional 62,635 shares during the quarter. ABN Amro Investment Solutions' holdings in Abbott Laboratories were worth $10,418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Freemont Management S.A. boosted its holdings in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new position in shares of Abbott Laboratories in the fourth quarter worth $116,580,000. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Abbott Laboratories in the third quarter worth $185,640,000. Thrivent Financial for Lutherans raised its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after buying an additional 48,286 shares in the last quarter. Finally, AE Wealth Management LLC raised its position in shares of Abbott Laboratories by 20.8% in the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker's stock worth $8,774,000 after buying an additional 11,264 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ABT. Weiss Ratings downgraded Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research report on Friday, April 24th. UBS Group lowered their price objective on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research report on Monday, April 20th. JPMorgan Chase & Co. lowered their price objective on Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Barclays lowered their price objective on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research report on Monday, April 20th. Finally, Wells Fargo & Company lowered their price objective on Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $119.43.

Abbott Laboratories Trading Down 0.7%

NYSE ABT opened at $87.72 on Friday. The stock's 50-day simple moving average is $97.19 and its two-hundred day simple moving average is $112.22. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $152.79 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 1.47 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the business posted $1.09 earnings per share. The company's revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.